The programmed death-1-ligand 1 (PD-L1) has been recently suggested to play a pivotal role in the immune evasion of tumors from host immune system. In the study, we tried to reveal the clinical significance of PD-L1 in patients with non-small cell lung cancer (NSCLC), which is one of the most aggressive and intractable malignant tumors.
Methods and study design
PD-L1 expression in 120 NSCLC tissue specimens and 10 benign control samples embedded with wax were retrospectively detected by immunohistochemistry.
Results
No PD-L1 was detected in the 10 benign controls, whereas 57.5% of NSCLC tissue specimens showed PD-L1 expression. There was no relationship between PD-L1 expression and patient age, gender or histopathological type. However, PD-L1 expression was significantly correlated to the degree of tumor cell differentiation, stage of tumor node metastasis (TNM) and patient survival. Poor tumor cell differentiation and advanced TNM stage were related to higher PD-L1 expression. PD-L1-negative NSCLC patients had longer overall 5-year survival than PD-L1-positive patients (P <0.0001). PD-L1 status was a significant independent prognostic factor of NSCLC (χ2 = 18.153, RR = 2.946, P <0.001).
Conclusions
Up-regulated PD-L1 expression in NSCLC is related to the degree of tumor cell differentiation and TNM stage. PD-L1 status may be a new predictor of prognosis for patients with NSCLC.
DongH., ZhuG., TamadaK., ChenL.: B7–H1, a third member of the B7 family, co-stimulates T-cell proliferation and interleukin-10 secretion.Nat Med, 5: 1365–1369, 1999.
7.
Kashani-SabetM.: Tumor progression by immune evasion in melanoma: role of the programmed cell death-1/programmed cell death-1 ligand 1 interaction.Cancer, 116: 1623–1625, 2010.
8.
DetterbeckF.C., BoffaD.J., TanoueL.T.: The new lung cancer staging system.Chest, 136: 260–271, 2009.
9.
Krleza-JeriK., LemmensT.: 7th revision of the Declaration of Helsinki: good news for the transparency of clinical trials.Croat Med J, 50: 105–110, 2009.
10.
BeasleyM.B., BrambillaE., TravisW.D.: The 2004 World Health Organization classification of lung tumors.Semin Roentgenol, 40: 90–97, 2005.
11.
TanoueL.T., DetterbeckF.C.: New TNM classification for non-small-cell lung cancer.Expert Rev Anticancer Ther, 9: 413–423, 2009.
12.
MuC.Y., HuangJ.A., ChenY., ChenC., ZhangX.G.: High expression of PD-L1 in lung cancer may contribute to poor prognosis and tumor cells immune escape through suppressing tumor infiltrating dendritic cells maturation.Med Oncol, 28: 682–688, 2011.
13.
FriedrichsK., GlubaS., EidtmannH., JonatW.: Overexpression of p53 and prognosis in breast cancer.Cancer, 72: 3641–3647, 1993.
14.
FreemanG.J., LongA.J., IwaiY., BourqueK., ChernovaT., NishimuraH.: Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation.J Exp Med, 192: 1027–1034, 2000.
15.
FingerL.R., PuJ., WassermanR., VibhakarR., LouieE., HardyR.R.: The human PD-1 gene: complete cDNA, genomic organization, and developmentally regulated expression in B cell progenitors.Gene, 197: 177–187, 1997.
16.
SharpeA.H., FreemanG.J.: The B7-CD28 superfamily.Nat Rev Immunol, 2: 116–126, 2002.
17.
WangL., MaQ., ChenX., GuoK., LiJ., ZhangM.: Clinical significance of b7-h1 and b7–1 expressions in pancreatic carcinoma.World J Surg, 34: 1059–1065, 2010.
18.
ThompsonR.H., GillettM.D., ChevilleJ.C., LohseC.M., DongH., WebsterW.S.: Costimulatory B7-H1 in renal cell carcinoma patients: Indicator of tumor aggressiveness and potential therapeutic target.Proc Natl Acad Sci U S A, 101: 17174–17179, 2004.
19.
ChenX., LiuS., WangL., ZhangW., JiY., MaX.: Clinical significance of B7-H1 (PD-L1) expression in human acute leukemia.Cancer Biol Ther, 7: 622–627, 2008.
20.
OhigashiY., ShoM., YamadaY., TsuruiY., HamadaK., IkedaN.: Clinical significance of programmed death-1 ligand-1 and programmed death-1 ligand-2 expression in human esophageal cancer.Clin Cancer Res, 11: 2947–2953, 2005.
21.
WuC., ZhuY., JiangJ., ZhaoJ., ZhangX.G., XuN.: Immunohistochemical localization of programmed death-1 ligand-1 (PD-L1) in gastric carcinoma and its clinical significance.Acta Histochem, 108: 19–24, 2006.
22.
GaoQ., WangX.Y., QiuS.J., YamatoI., ShoM., NakajimaY.: Overexpression of PD-L1 significantly associates with tumor aggressiveness and postoperative recurrence in human hepatocellular carcinoma.Clin Cancer Res, 15: 971–979, 2009.
23.
NomiT., ShoM., AkahoriT., HamadaK., KuboA., KanehiroH.: Clinical significance and therapeutic potential of the programmed death-1 ligand/programmed death-1 pathway in human pancreatic cancer.Clin Cancer Res, 13: 2151–2157, 2007.
24.
GengL., HuangD., LiuJ., QianY., DengJ., LiD.: B7-H1 up-regulated expression in human pancreatic carcinoma tissue associates with tumor progression.J Cancer Res Clin Oncol, 134: 1021–1027, 2008.
25.
NakanishiJ., WadaY., MatsumotoK., AzumaM., KikuchiK., UedaS.: Overexpression of B7-H1 (PD-L1) significantly associates with tumor grade and postoperative prognosis in human urothelial cancers.Cancer Immunol Immunother, 56: 1173–1182, 2007.
26.
TunuguntlaH.S., JordaM.: Diagnostic and prognostic molecular markers in renal cell carcinoma.J Urol, 179: 2096–2102, 2008.
RouthJ.C., AshleyR.A., SeboT.J., LohseC.M., HusmannD.A., KramerS.A.: B7-H1 expression in Wilms tumor: correlation with tumor biology and disease recurrence.J Urol, 179: 1954–1959, 2008.
29.
HamanishiJ., MandaiM., IwasakiM., OkazakiT., TanakaY., YamaguchiK.: Programmed cell death 1 ligand 1 and tumor-infiltrating CD8+ T lymphocytes are prognostic factors of human ovarian cancer.Proc Natl Acad Sci U S A, 104: 3360–3365, 2007.
30.
GhebehH., MohammedS., Al-OmairA., QattanA., LeheC., Al-QudaihiG.: The B7-H1 (PD-L1) T lymphocyte-inhibitory molecule is expressed in breast cancer patients with infiltrating ductal carcinoma: correlation with important high-risk prognostic factors.Neoplasia, 8: 190–198, 2006.
31.
KonishiJ., YamazakiK., AzumaM., KinoshitaI., Dosaka-AkitaH., NishimuraM.: B7-H1 expression on non-small cell lung cancer cells and its relationship with tumor-infiltrating lymphocytes and their PD-1 expression.Clin Cancer Res, 10: 5094–5100, 2004.
IwaiY., IshidaM., TanakaY., OkazakiT., HonjoT., MinatoN.: Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade.Proc Natl Acad Sci U S A.99: 12293–12297, 2002.
34.
TamuraH., OgataK., DongH., ChenL.: Immunology of B7-H1 and its roles in human diseases.Int J Hematol, 78: 321–328, 2003.
35.
BlankC., GajewskiT.F., MackensenA.: Interaction of PD-L1 on tumor cells with PD-1 on tumor-specific T cells as a mechanism of immune evasion: implications for tumor immunotherapy.Cancer Immunol Immunother, 54: 307–314, 2005.
36.
BlankC., MackensenA.: Contribution of the PD-L1/PD-1 pathway to T-cell exhaustion: an update on implications for chronic infections and tumor evasion.Cancer Immunol Immunother, 56: 739–745, 2007.
37.
BlankC., KuballJ., VoelklS., WiendlH., BeckerB., WalterB.: Blockade of PD-L1 (B7-H1) augments human tumor-specific T cell responses in vitro.Int J Cancer, 119: 317–327, 2006.
38.
TsushimaF., YaoS., ShinT., FliesA., FliesS., XuH.: Interaction between B7-H1 and PD-1 determines initiation and reversal of T-cell anergy.Blood, 110: 180–185, 2007.
39.
AzumaT., YaoS., ZhuG., FliesA.S., FliesS.J., ChenL.: B7-H1 is a ubiquitous antiapoptotic receptor on cancer cells.Blood, 111: 3635–3643, 2008.
